Alzheimer’s dementia: budget impact and cost-utility analysis of a combination treatment with a cholinesterase inhibitor and memantine in Switzerland

Alzheimer’s dementia: budget impact and cost-utility analysis of a combination treatment with a cholinesterase inhibitor and memantine in Switzerland

QUESTIONS UNDER STUDY: The objective of this study was to estimate the potential budget impact and cost-effectiveness of the combination treatment of a cholinesterase inhibitor and memantine in Switzerland. METHODS: The prevalence of dementia according to European sources and future...

Bibliográfalaš dieđut
Váldodahkkit:	Alena M. Pfeil, Reto W. Kressig, Thomas D. Szucs
Materiálatiipa:	Artihkal
Giella:	English
Almmustuhtton:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2012-11-01
Ráidu:	Swiss Medical Weekly
Fáttát:	Alzheimer’s dementia budget impact analysis cholinesterase inhibitor Cost cost-effectiveness analysis cost-utility analysis
Liŋkkat:	https://www.smw.ch/index.php/smw/article/view/1621

Geahča maid

Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer’s Disease and Other Dementias
Dahkki: Taim Muayqil, et al.
Almmustuhtton: (2012-11-01)

Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis
Dahkki: Dominik Glinz, et al.
Almmustuhtton: (2019-06-01)

A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
Dahkki: Ione Ayala Gualandi de Oliveira, et al.
Almmustuhtton: (2019-11-01)

Cost utility, budget impact, and scenario analysis of racecadotril in addition to oral rehydration for acute diarrhea in children in Malaysia
Dahkki: Rautenberg TA, et al.
Almmustuhtton: (2018-03-01)

Cost of dementia in Switzerland
Dahkki: E Kraft, et al.
Almmustuhtton: (2010-08-01)

Position Statement on Anti-Dementia Medication for Alzheimer’s Disease by Swiss Stakeholders
Dahkki: Giovanni B Frisoni, et al.
Almmustuhtton: (2021-08-01)

Costs Related to Frontotemporal Dementia in Latin America: A Scoping Review of Economic Health Studies
Dahkki: Carlos Alva-Dìaz, et al.
Almmustuhtton: (2021-08-01)

Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer’s Dementia Are Frequently Below the Recommended Levels
Dahkki: Marion Ortner, et al.
Almmustuhtton: (2020-05-01)

Annual societal cost of Alzheimer’s disease in Malaysia: a micro-costing approach
Dahkki: Siew Chin Ong, et al.
Almmustuhtton: (2025-03-01)

FINANCIAL AVAILABILITY OF IN-HOME MEDICAL TREATMENT OF PATIENTS WITH ALZHEIMER’S DISEASE
Dahkki: Mariana Arnaoudova, et al.
Almmustuhtton: (2016-07-01)

Systematic Review of Cholinesterase Inhibitors on Cognition and Behavioral Symptoms in Patients of Chinese Descent with Alzheimer’s Disease, Vascular Dementia, or Mixed Dementia
Dahkki: Ka-Chun Leung, et al.
Almmustuhtton: (2017-08-01)

Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimer’s disease
Dahkki: Javier Mar, et al.
Almmustuhtton: (2020-12-01)

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
Dahkki: Noll Campbell, et al.
Almmustuhtton: (2008-12-01)

Cost–utility analysis of adapted problem adaptation therapy for depression in mild-to-moderate dementia caused by Alzheimer's disease: PATHFINDER randomised controlled trial
Dahkki: Monica Panca, et al.
Almmustuhtton: (2024-11-01)

Hospitalization budget impact during the COVID-19 pandemic in Spain
Dahkki: F. J. Carrera-Hueso, et al.
Almmustuhtton: (2021-11-01)

Reassessment of the dementia diagnosis of Alzheimer's disease in patients enrolled on the cholinesterase inhibitors dispensation program
Dahkki: Magda Cristina Flaitt Sanches Piovesana, et al.

Budget impact analysis of dexamethasone intravitreal implant for the treatment of diabetic macular oedema
Dahkki: Fernando de Andrés-Nogales, et al.
Almmustuhtton: (2018-11-01)

Persistence of Cholinesterase Inhibitor Treatment in Dementia: Insights from a Naturalistic Study
Dahkki: Javier Olazarán, et al.
Almmustuhtton: (2013-03-01)

Cost of care for persons with dementia: using a discrete-time Markov chain approach with administrative and clinical data from the dementia service Centres in Austria
Dahkki: Alexander Braun, et al.
Almmustuhtton: (2020-09-01)

PHARMACOECONOMIC ANALYSIS OF THE IMPACT ON THE BUDGET COSTS OF ADDING DEXMEDETOMIDINE (DEXDOR) INTO THE LIST OF VITAL AND ESSENTIAL DRUGS
Dahkki: S. L. Plavinskiy, et al.
Almmustuhtton: (2017-11-01)

Open Meter Duo: Low-Cost Instrument for Fluorimetric Determination of Cholinesterase Activity
Dahkki: Ondřej Keresteš, et al.
Almmustuhtton: (2024-03-01)

Trends and disparities in the use of cholinesterase inhibitors to treat Alzheimer’s disease dispensed by the Brazilian public health system – 2008 to 2014: a nation-wide analysis
Dahkki: Flávia Silva de Moraes, et al.

BUDGETING AS A MECHANISM TO CONTROL THE COSTS OF AGRICULTURAL ENTERPRISES
Dahkki: Zotov V.P., et al.
Almmustuhtton: (2016-03-01)

Economic Evaluation of Cataract: A Systematic Mapping Review
Dahkki: José Ginel, et al.
Almmustuhtton: (2023-02-01)

COST BUDGETING WITH THE ROMANIAN BAKERY UNITS
Dahkki: RĂSCOLEAN ILIE, et al.
Almmustuhtton: (2017-11-01)

Economic Evaluation of Health Interventions: A Critical Review
Dahkki: Ali Mohammad Mosadeghrad, et al.
Almmustuhtton: (2022-10-01)

A Comparison of Cost-Benefit and Cost-Effectiveness Analysis in Practice: Divergent Policy Practices in Sweden
Dahkki: Mikael Svensson, et al.
Almmustuhtton: (2017-02-01)

‘FLEXIBLE’ BUDGETS ARE ALREADY BUDGETING PROCESS ANALYSIS OF PRODUCTION COSTS FOR OIL AND FAT ENTERPRISES
Dahkki: V. Shvetz’, et al.
Almmustuhtton: (2013-10-01)

Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study
Dahkki: Willem S. Eikelboom, et al.
Almmustuhtton: (2019-05-01)

Determination of Directions to Increase the Efficiency of Municipal Budget Funds Spending
Dahkki: E. V. Orlov, et al.
Almmustuhtton: (2023-07-01)

Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
Dahkki: Saharat Aungsumart, et al.
Almmustuhtton: (2023-10-01)

Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain
Dahkki: Javier Mar, et al.
Almmustuhtton: (2022-11-01)

Exploring costs, cost components, and associated factors among people with dementia approaching the end of life: A systematic review
Dahkki: Javiera Leniz, et al.
Almmustuhtton: (2021-01-01)

The economic impact of two diagnostic strategies in the management of restorations in primary teeth: a health economic analysis plan for a trial-based economic evaluation
Dahkki: Raíza Dias Freitas, et al.
Almmustuhtton: (2021-11-01)

Cost-effectiveness of Descemet stripping automated endothelial keratoplasty versus penetrating keratoplasty in patients with endothelial dysfunction in India
Dahkki: Pooja Shah, et al.
Almmustuhtton: (2021-01-01)

Which factors increase informal care hours and societal costs among caregivers of people with dementia? A systematic review of Resource Utilization in Dementia (RUD)
Dahkki: Renira C. Angeles, et al.
Almmustuhtton: (2021-09-01)

Economic evaluation of vaccination against COVID‐19: A systematic review
Dahkki: Dolatshahi Zeinab, et al.
Almmustuhtton: (2024-02-01)

Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost–Utility and Budget Impact Analysis
Dahkki: Iñaki Imaz-Iglesia, et al.
Almmustuhtton: (2024-07-01)

A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis
Dahkki: Nor Zam Azihan Mohd Hassan, et al.
Almmustuhtton: (2022-12-01)

A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina
Dahkki: Agostino Fortunato, et al.
Almmustuhtton: (2024-03-01)